INCR News & Events

InterCure announced that the company received a written notice from Nasdaq indicating that the company was not in compliance with Nasdaq Listing Rule 5450, as the company's closing bid price for its ordinary shares, or ordinary shares, was below $1.00 per share for the last 30 consecutive business days. Pursuant to Nasdaq Listing Rule 5810, the company has been granted a 180-calendar day compliance period, or until August 24 to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the ordinary shares must meet or exceed $1.00 per share for at least 10 consecutive business days during the 180-calendar day compliance period. If the company is not in compliance by August 24, the company expects to be eligible for an additional 180-calendar day compliance period.

Adjusted EBITDA is expected to be positive in both the first and second halves of 2025, marking the Company's twelfth consecutive half-year of positive Adjusted EBITDA. Cash on hand of NIS 43M as of December 31, 2025. Alexander Rabinovich, CEO noted: "2025 marked a year of disciplined execution and renewed growth for InterCure. We delivered meaningful acceleration in the second half of the year with nearly 20% revenue growth and achieved our twelfth consecutive half-year of positive Adjusted EBITDA. The anticipated commencement of operations under the Botanico transaction and our strategic collaboration with Cannasoul are expected to further strengthen our pharmaceutical platform and global positioning. This marks another key milestone with our first significant revenues in the German market, as we expect continued execution of our global expansion strategy in Germany and additional markets throughout 2026. As regulatory frameworks continue to evolve, particularly in the United States and Europe, we believe InterCure is strategically positioned to leverage its vertically integrated model, scientific leadership, and international partnerships to drive long-term value for patients and shareholders."

InterCure announced it has entered into a definitive Share Purchase Agreement and a Collaboration Agreement with Cannasoul R&D. The Share Purchase Agreement provides InterCure with a 28% ownership position in Cannasoul on a fully diluted basis and an exclusive path to increase its holdings to 51% within two years, while the Collaboration Agreement formalizes a partnership in research, development, and commercialization of evidence-based cannabis therapeutics.

Alexander Rabinovitch, CEO of InterCure, stated: "In the first half of 2025, InterCure delivered revenues of NIS 130 million, achieving positive Adjusted EBITDA for the eleventh consecutive half year period and generating NIS 12 million in positive operating cash flow. This performance underscores the strength of our vertically integrated business model and our ability to navigate a challenging environment, including the impact of the October 7 attack and the ongoing war in Gaza. We continue to work closely with Israeli authorities to secure full compensation for damages to our southern facility. Looking ahead, we are confident in our ability to continue our recovery growth trajectory, expanding our international footprint, and strengthen our leadership in the pharmaceutical cannabis industry, particularly with the strategic acquisition of ISHI, which positions us to capitalize on evolving opportunities in the global cannabis market. At the same time, we are closely monitoring regulatory developments in the U.S. regarding potential rescheduling of cannabis."